Gendel

About:

Gendel develops a proprietary platform technology for the localized delivery of biological molecules to target sites within the body.

Top Investors: Scottish Equity Partners, Invest Northern Ireland, Crescent Capital, Enterprise Equity

Description:

Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.